# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | IHH HEALTHCARE BERHAD |
| Establishment Date | N/A |
| Headquarters Location | Kuala Lumpur, Malaysia |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | IHH Healthcare integrates advanced medical technologies such as AI-powered diagnostic tools (e.g., SenseCare Chest CT, Lunit INSIGHT MMG, Annalise AI) and pioneering treatments like Upright Photon Therapy and robot-assisted surgery. The Group employs a Clinical Risk Assurance Framework and a robust Clinical Governance framework, including clinical audits and a multi-tiered risk management approach. It also fosters innovation through initiatives like the I.GLOBE Custom Hospital Business Simulation and the IHH Research and Innovation Grant, and advances AI governance to ensure ethical and effective integration. | IHH Healthcare demonstrates innovation through the adoption of advanced medical technologies such as the O-Arm imaging and navigation system at Prince Court Medical Centre, proton beam therapy at Mount Elizabeth Novena Hospital, and Ethos radiotherapy in Türkiye. The Group integrates artificial intelligence (AI) to improve disease diagnostics and employs digital healthcare applications including MyHealth360 for patient health management and AI-driven bill estimates. The Enterprise Risk Management (ERM) framework incorporates sustainability and ESG risks, supported by a robust clinical governance framework and continuous clinical quality indicator reviews to enhance patient safety and care outcomes. |
| Product Advantages | IHH Healthcare operates a diversified portfolio of over 140 healthcare facilities, including more than 80 hospitals across 10 countries, offering a full spectrum of integrated healthcare services from primary to quaternary care, including diagnostics, laboratory testing, and rehabilitation. The portfolio includes well-known brands such as Acibadem, Fortis, Gleneagles, Island, Mount Elizabeth, Pantai, and Parkway, with specialized services like genomics and advanced cancer treatments. The Group continuously expands capacity and service offerings, including ambulatory care and primary care clinics, to meet growing demand and enhance clinical excellence. | IHH Healthcare offers a broad portfolio of healthcare services across over 80 hospitals in 10 countries, including specialized cancer treatments such as proton beam therapy and CAR T-cell therapy. The Group's brands, including Mount Elizabeth, Parkway, Gleneagles, Pantai, Fortis Healthcare, and Prince Court, provide integrated healthcare services encompassing hospitals, clinics, laboratories, and ancillary services. The laboratory business is a growing segment with 96 million tests conducted across four markets, supported by advanced diagnostic technologies like digital PET CT and FAPI PET/CT scans. |
| Brand Recognition | IHH Healthcare is recognized as a leading international healthcare network with established brands that have strong reputations for clinical outcomes and quality care. The Group received multiple prestigious awards in 2024, including FinanceAsia Asia's Best Company Awards and Corporate Governance Asia's Asian Excellence Awards, highlighting leadership in investor relations, corporate governance, and financial management. It is also acknowledged for thought leadership through its HealthcareInsider series and maintains long-term relationships with stakeholders via transparent communication and active investor engagement. | IHH Healthcare is recognized as a leading private healthcare provider with strong brand presence in multiple markets, including Singapore, Malaysia, India, and Türkiye. The Group's hospitals, such as Mount Elizabeth and Gleneagles, are noted for clinical excellence and personalized care. IHH received multiple accolades in 2023, including Institutional Investor's Asia Pacific Executive Team rankings, Time magazine's 'World's Best Companies', and the 'Most Outstanding Company in Singapore - Healthcare Sector' by Asiamoney. The Group also won awards for ESG reporting and community health outreach programs. |
| Reputation Ratings | IHH Healthcare demonstrates strong governance and sustainability practices, with a Board-led oversight of integrated sustainability goals and risk management aligned with ESG principles. The Group has received awards such as the National Corporate Governance & Sustainability Awards (NACGSA) Excellence Award 2024 and is ranked in TIME's World's Best Companies 2024. It actively manages climate-related risks and opportunities, adheres to international accreditation standards like JCI and MSQH, and commits to transparent corporate reporting and stakeholder engagement, including compliance with IFRS S2 climate-related disclosures by 2025. | IHH Healthcare maintains a comprehensive sustainability framework aligned with ESG principles, integrating sustainability into its business strategy and risk management processes. The Group's sustainability governance includes a Board-level Sustainability Committee and links sustainability KPIs to executive remuneration. IHH received the Best ESG Reporting (Large Cap) award at the IR Magazine Awards South East Asia 2023 and has established policies for ethical conduct, risk management, and compliance with international accreditation standards such as JCI, MSQH, and NABH. The Group is progressing towards alignment with the Task Force on Climate-Related Financial Disclosures (TCFD) recommendations. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | At IHH, we are united by our shared commitment to touch lives and transform care for patients and communities worldwide. |
| Vision Statement | To be the world's most trusted healthcare services network |
| Core Values | Patients First, Integrity, Empathy, Teamwork, Excellence |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 24,383.0 | 20,935.0 | 17,988,687.0 | Millions | RM |
| Cost of Goods Sold | (6,811.0) | (4,389.0) | (5,497,553.0) | Millions | RM |
| Gross Profit | 17,572.0 | 16,546.0 | 12,491,134.0 | Millions | RM |
| Operating Expense | (5,590.0) | (5,170.0) | (11,194,942.0) | Millions | RM |
| Operating Income | 11,982.0 | 11,376.0 | 1,292,192.0 | Millions | RM |
| Net Profit | 3,162.0 | 3,391.0 | 1,645,142.0 | Millions | RM |
| Income before income taxes | 3,756.0 | 4,049.0 | 2,217,091.0 | Millions | RM |
| Income tax expense(benefit) | (594.0) | (658.0) | (571,949.0) | Millions | RM |
| Interest Expense | (1,065.0) | (941.0) | (657,413.0) | Millions | RM |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | N/A | N/A | N/A | N/A | N/A |
| Current Assets | N/A | N/A | N/A | N/A | N/A |
| Non-Current Assets | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | N/A | N/A | N/A | N/A | N/A |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Non-Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Shareholders' Equity | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A |
| Total Equity and Liabilities | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A |
| Prepaid Expenses | N/A | N/A | N/A | N/A | N/A |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | N/A | N/A | N/A | N/A | N/A |
| Net Cash Flow from Investing | N/A | N/A | N/A | N/A | N/A |
| Net Cash Flow from Financing | N/A | N/A | N/A | N/A | N/A |
| Net Increase/Decrease in Cash | N/A | N/A | N/A | N/A | N/A |
| Dividends | N/A | N/A | N/A | N/A | N/A |


## S2.4: Key Financial Metrics

|       | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Profit Margin | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A |
| Debt-to-Equity | N/A | N/A | N/A |
| Interest Coverage | N/A | N/A | N/A |
| Asset Turnover | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Effective Tax Rate | N/A | N/A | N/A | 
| Dividend Payout Ratio | N/A | N/A | N/A |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | N/A | N/A | N/A |
| Revenue by Geographic Region | N/A | N/A | N/A |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | N/A |
| Operating Efficiency | N/A |
| External & One-Off Impact | N/A |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | N/A | N/A |
| Profitability and earnings quality | N/A | N/A |
| Operational efficiency | N/A | N/A |
| Financial risk identification and early warning | N/A | N/A |
| Future financial performance projection | N/A | N/A |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | N/A | N/A |
| Market Position | N/A | N/A |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | N/A | N/A |
| Operational Risks | N/A | N/A |
| Financial Risks | N/A | N/A |
| Compliance Risks | N/A | N/A |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| N/A | N/A | N/A |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | N/A | N/A |
| Control activities | N/A | N/A |
| Monitoring mechanisms | N/A | N/A |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | N/A | N/A |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | N/A | N/A |
| New technologies | N/A | N/A |
| Organisational Restructuring | N/A | N/A |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | N/A | N/A |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | N/A | N/A |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | N/A | N/A |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | N/A | N/A |
